A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
The prevalence of dementia in the Western world in people over the age of 60 has been estimated to be greater than 5%, about two-thirds of which are due to Alzheimer's disease. The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3). Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders. We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease. This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease. Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nearly 30 LOAD susceptibility loci2-12 are known, and risk is significantly polygenic13.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“Recent sequencing studies identified a number of genes that have rare variants associated with AD9-11,18-24.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“The NH2-terminal APP A673T(Icelandic) mutation, however, makes APP a less favorable substrate for 𝛃 -secretase, resulting in decreased A 𝛃 production (299).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [299]
In the citing paper
“This observation is also true for the rare variant p.A673T (rs63750847) in APP, which was identified in Icelanders and was shown to have a strong protective effect against age-related cognitive decline as well as AD [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
In the citing paper
“The p.A673T variant was observed in control subjects aged over 85 years at a frequency of 0.45%, which is higher than that seen in AD patients [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
A new multipoint method for genome-wide association studies by imputation of genotypes
Marchini, J., Howie, B., Myers, S., McVean, G., & Donnelly, P. (2007) · Nature Genetics · doi:10.1038/ng2088 · Cited by 2,609
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932
MDS Cognitive Performance Scale(C)
Morris, J. N., Fries, B. E., Mehr, D. R., Hawes, C., Phillips, C., Mor, V., & Lipsitz, L. A. (1994) · Journal of Gerontology · doi:10.1093/geronj/49.4.m174 · Cited by 1,810
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Cited by
Items 901–1,000 of 1,008
Apolipoprotein E impairs amyloid‐β fibril elongation and maturation
Islam, T., Gharibyan, A. L., Surano, S., Pettersson, N., Brännström, K., Hedberg, I., Virta, M., Olofsson, L., & Olofsson, A. (2019) · FEBS Journal · doi:10.1111/febs.15075 · Cited by 21
Wang, Z., Dong, X., & Sun, Y. P. (2019) · Langmuir · doi:10.1021/acs.langmuir.9b02527 · Cited by 20
Protective effects of grape seed procyanidin on isoflurane-induced cognitive impairment in mice
Gong, X., Xu, L., Fang, X., Zhao, X., Du, Y., Wu, H., Qian, Y., Ma, Z., Xia, T., & Gu, X. (2020) · Pharmaceutical Biology · doi:10.1080/13880209.2020.1730913 · Cited by 20
“Previous studies showed that, in Western countries, the prevalence of dementia in people over 60 is greater than 5%, and nearly doubles every 5 years after the age of 65, comprising about 50 million individuals worldwide (Plassman et al. 2007; Jonsson et al. 2012).”
BackgroundHassan, S. A., & Kadry, M. O. (2020) · Biological Trace Element Research · doi:10.1007/s12011-020-02132-9 · Cited by 23
Imbimbo, B. P., Ippati, S., & Watling, M. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1793755 · Cited by 21
Guyon, A., Rousseau, J., Lamothe, G., & Tremblay, J. P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237122 · Cited by 22
“concluded that the A673T mutation confers a strong protection against AD [19].”
BackgroundInfluentialExome Sequencing: New Insights into Lipoprotein Disorders
Farhan, S. M. K., & Hegele, R. A. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0507-2 · Cited by 23
Genomic Discoveries and Personalized Medicine in Neurological Diseases
Zhang, L., & Hong, H. (2015) · Pharmaceutics · doi:10.3390/pharmaceutics7040542 · Cited by 22
“[24] identified A673T in the APP gene that protects against AD and cognitive decline in the elderly without AD.”
Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease
Bu, X., Jiao, S., Lian, Y., & Wang, Y. (2015) · Current Alzheimer Research · doi:10.2174/1567205013666151215110114 · Cited by 22
“The compelling finding that a rare mutation in the APP gene decreases Aβ production and protects against late-onset AD also confirms the causative role of Aβ in AD pathogenesis [40].”
BackgroundBlain, J., Bursavich, M. G., Freeman, E. A., Hrdlicka, L., Hodgdon, H., Chen, T., Costa, D., Harrison, B. A., Kapadnis, S., Murphy, D. A., et al. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0199-5 · Cited by 21
“A protective mutation in APP has also been reported to delay disease onset and has been linked to decreased production and aggregation of Aβ [39, 40].”
Mutations modifying sporadic Alzheimer’s disease age of onset
Vélez, J. I., Lopera, F., Patel, H. R., Johar, A. S., Cai, Y., Rivera, D., Tobón, C., Villegas, A., Sepulveda‐Falla, D., Lehmann, S. G., et al. (2016) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32493 · Cited by 19
Alzheimer’s disease basics: we all should know
Das, S. K. (2025) · Neurological Research · doi:10.1080/01616412.2025.2529560 · Cited by 21
“In humans, carriers of the A673T variation had plasma levels of Aβ 40 and Aβ 42 that are about 28% lower than those of control people [282,283].”
Pennington, L. D., Whittington, D. A., Bartberger, M. D., Jordan, S. R., Monenschein, H., Nguyen, T. T. H., Yang, B. H., Xue, Q., Vounatsos, F., Wahl, R. C., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.028 · Cited by 19
New Mechanism of Amyloid Fibril Formation
Galzitskaya, O. V. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190125160937 · Cited by 19
Neuronal KCNQ2/3 channels are recruited to lipid raft microdomains by palmitoylation of BACE1
Dai, G. (2022) · The Journal of General Physiology · doi:10.1085/jgp.202112888 · Cited by 23
“A single mutation in APP that compromises the ability of BACE1 to cleave APP can reduce Aβ generation and slow the progression of AD (Di Fede et al., 2009; Jonsson et al., 2012).”
BackgroundPeng, X.-L., Hou, L., Xu, S., Hua, Y., Zhou, S.-J., Zhang, Y., Zheng, Y.-P., Fu, Y.-H., Xu, Q., Zhang, L.-S., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.005 · Cited by 21
Mosley, J. D., Driest, S. L. V., Larkin, E. K., Weeke, P., Witte, J. S., Wells, Q. S., Karnes, J. H., Guo, Y. P., Bastarache, L. A., Olson, L. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081503 · Cited by 21
Examination of Candidate Exonic Variants for Association to Alzheimer Disease in the Amish
D’Aoust, L. N., Cummings, A. C., Laux, R. A., Fuzzell, D., Caywood, L. J., Reinhart‐Mercer, L., Scott, W. K., Pericak‐Vance, M. A., & Haines, J. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118043 · Cited by 21
A tale of two drug targets: the evolutionary history of BACE1 and BACE2
Southan, C., & Hancock, J. M. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00293 · Cited by 19
“Thirdly, there has been new, indirect genetic target validation in the form of an A673T mutation in APP that was AD-protective due to reduced BACE1 cleavage (Jonsson et al., 2012).”
BackgroundInfluentialHashimoto, Y., & Matsuoka, M. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12717 · Cited by 20
“The A673T mutation, corresponding to the A598T mutation in the most prevalent neuronal APP isoform APP695, has recently been found to be linked to a reduction in the occurrence of AD (Jonsson et al. 2012).”
BackgroundMolecular Pathology of Alzheimer's Disease
Castellani, R. J., & Perry, G. L. (2013) · Colloquium Series on Neurobiology of Alzheimer s Disease · doi:10.4199/c00095ed1v01y201310alz001 · Cited by 22
Sy, L., Lok, C., Wang, J., Liu, Y., Cheng, L., Wan, P., Leung, C.-T., Cao, B., Kwong, W., Chang, R. C., et al. (2016) · Chemical Science · doi:10.1039/c5sc02377g · Cited by 20
Self-citationThomas, A. A., Hunt, K. W., Newhouse, B., Watts, R. J., Liu, X., Vigers, G. P. A., Smith, D. J., Rhodes, S. P., Brown, K. D., Otten, J. N., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5015132 · Cited by 24
Self-citationReconstructing an African haploid genome from the 18th century
Jagadeesan, A., Gunnarsdóttir, E. D., Ebenesersdóttir, S. S., Guðmundsdóttir, V. B., Þórðardóttir, E. L., Einarsdóttir, M. S., Jónsson, H., Dugoujon, J., Fortes‐Lima, C., Migot‐Nabias, F., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0031-6 · Cited by 23
Self-citationAlber, J., McGarry, K., Noto, R. B., & Snyder, P. J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00060 · Cited by 19
“Despite recent developments indicating other genetic contributions to AD such as APP and TREM2 (Jonsson et al., 2012, 2013; Guerreiro et al., 2013), a large proportion of the genetic variance in AD remains unaccounted for.”
BackgroundAllosteric sodium binding cavity in GPR3: a novel player in modulation of Aβ production
Capaldi, S., Suku, E., Antolini, M., Giacobbe, M. D., Giorgetti, A., & Buffelli, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-29475-7 · Cited by 20
Forman, M. S., Palcza, J. S., Tseng, J., Stone, J. A., Walker, B., Swearingen, D., Troyer, M. D., & Dockendorf, M. F. (2019) · Clinical and Translational Science · doi:10.1111/cts.12645 · Cited by 20
Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies
Galzitskaya, O. V. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00319 · Cited by 19
Substrate recruitment by γ-secretase
Fukumori, A., Feilen, L. P., & Steiner, H. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.03.006 · Cited by 22
Michno, W., Blennow, K., Zetterberg, H., & Brinkmalm, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15466 · Cited by 19
“Recently, another protective mutation, APP A673T, known as the Icelandic mutation, was reported (Jonsson et al., 2012).”
BackgroundCurrent Drug Targets in Alzheimer’s Associated Memory Impairment: A Comprehensive Review
Chandrashekar, K. S., Mathew, A., Vignesh Balaji, E., Pai, K. S. R., Kishore, A., Pai, V., & Pemmireddy, R. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220401124719 · Cited by 20
A novel bio-inspired strategy to prevent amyloidogenesis and synaptic damage in Alzheimer’s disease
Catania, M., Colombo, L., Sorrentino, S., Cagnotto, A., Lucchetti, J., Barbagallo, M., Vannetiello, I., Vecchi, E. R., Favagrossa, M., Costanza, M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01745-x · Cited by 19
“A protective effect against AD and aging-related cognitive decline was claimed in the Icelander population for another Aβ variant (AβA2T) consisting of an alanineto-threonine substitution at the same codon of the A2V mutation [18].”
BackgroundDiomede, L., Zanier, E. R., Moro, F., Vegliante, G., Colombo, L., Russo, L., Cagnotto, A., Natale, C., Xodo, F. M., Luigi, A. D., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02101-3 · Cited by 20
Galasko, D., Farlow, M. R., Lucey, B. P., Honig, L. S., Elbert, D. L., Bateman, R. J., Momper, J. D., Thomas, R. G., Rissman, R. A., Pa, J., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01490-z · Cited by 24
“An APP mutation associated with decreased production of Aβ protects against late onset AD [9].”
Abraham, J.-D., Promé, S., Salvetat, N., Rubrecht, L., Cobo, S., Paty, E. D., Galéa, P., Mathieu‐Dupas, E., Ranaldi, S., Caillava, C., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.58 · Cited by 20
Murakami, K., Watanabe, T., Koike, T., Kamata, M., Igari, T., & Kondo, S. (2015) · Brain Research · doi:10.1016/j.brainres.2015.12.016 · Cited by 22
Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors
Wu, Y., Guernon, J. M., Rajamani, R., Toyn, J. H., Ahlijanian, M. K., Albright, C. F., Muckelbauer, J. K., Chang, C. Y., Camac, D., Macor, J. E., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.055 · Cited by 19
Petrushina, I., Davtyan, H., Hovakimyan, A., Davtyan, A., Passos, G. F., Cribbs, D. H., Ghochikyan, A., & Agadjanyan, M. G. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.002 · Cited by 20
Interactions within the MHC contribute to the genetic architecture of celiac disease
Goudey, B., Abraham, G., Kikianty, E., Wang, Q., Rawlinson, D., Shi, F., Haviv, I., Stern, L., Kowalczyk, A., & Inouye, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172826 · Cited by 22
Low, J. D., Bartberger, M. D., Chen, K., Cheng, Y., Fielden, M. R., Gore, V., Hickman, D., Liu, Q., Sickmier, E. A., Vargas, H. M., et al. (2017) · MedChemComm · doi:10.1039/c7md00106a · Cited by 19
Colombo, L., Gamba, A., Cantú, L., Salmona, M., Tagliavini, F., Rondelli, V., Favero, E. D., & Brocca, P. (2017) · Biophysical Chemistry · doi:10.1016/j.bpc.2017.05.001 · Cited by 18
Polak, T. T., Herrmann, M. J., Müller, L. D., Zeller, J. B. M., Katzorke, A., Fischer, M., Spielmann, F., Weinmann, E., Hommers, L. G., Lauer, M., et al. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1781-0 · Cited by 22
BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains
Čaušević, M., Dominko, K., Malnar, M., Vidatic, L., Čermak, S., Pigoni, M., Kuhn, P., Colombo, A. V., Havas, D., Flunkert, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200344 · Cited by 20
Trends of Protein Aggregation in Neurodegenerative Diseases
Aǵbaş, A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81224 · Cited by 20
“Levels of γ- and β-secretase activities are greater in brain tissue samples from AD patients than non-demented control subjects [68, 69].”
BackgroundPrzygońska, K., Pacewicz, M., Sadowska, W., Poznański, J. T., Bal, W., & Dadlez, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-45988-1 · Cited by 19
The search for Alzheimer disease therapeutics — same targets, better trials?
Rafii, M. S., & Aisen, P. S. S. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-00414-3 · Cited by 19
Experimental approaches for altering the expression of Abeta‐degrading enzymes
Loeffler, D. A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15762 · Cited by 20
“…finding that a rare mutation at the β- secretase site, the “Icelandic mutation” (A673T), which was found to reduce in vitro formation of amyloidogenic Aβ species by 40%, decreased the risk for developing either age- related cognitive impairment or AD (Jonsson et al., 2012; Maloney et al., 2014).”
BackgroundThe Role of Gene Editing in Neurodegenerative Diseases
Fan, H.-C., Chi, C.-S., Lee, Y.-J., Tsai, J., Lin, S., & Harn, H.-J. (2018) · Cell Transplantation · doi:10.1177/0963689717753378 · Cited by 23
Przygońska, K., Poznański, J. T., Mistarz, U. H., Rand, K. D., & Dadlez, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201761 · Cited by 19
“, A2V, H6R-English, D7N-Tottori, D7H-Taiwanese) or may be protective (A2T) [61].”
Selective agonism of GPR34 stimulates microglial uptake and clearance of amyloid β fibrils
Etani, H., Takatori, S., Wang, W., Omi, J., Amiya, Y., Akahori, A., Watanabe, H., Sonn, I., Okano, H., Hara, N., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01891-8 · Cited by 16
“Conversely, the APP A673T variant, which is associated with lower Aβ levels, significantly reduces the risk of late-onset AD [2].”
Zhang, Y., Xie, X., Chen, B., Pan, L., Li, J., Wang, W., Wang, J., Tang, R., Huang, Q., Chen, X., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.051 · Cited by 20
“APP A673T is the only identified protective APP mutation that reduces the generation of amyloidogenic Ab peptides by approximately 40% in vitro and protects against cognitive decline in elderly individuals without AD.(23,24) The other mutation, APP A673V, was associated with recessive inheritance of AD, which differs…”
BackgroundInfluentialKobro‐Flatmoen, A., Hormann, T. M., & Gouras, G. K. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230349 · Cited by 20
Recent advances in Alzheimer disease genetics
Nicolas, G. (2024) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001242 · Cited by 19
Wang, J., Gleeson, P. A., & Fourriere, L. (2024) · Traffic · doi:10.1111/tra.12932 · Cited by 18
Cohen, E. (2012) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10088 · Cited by 19
Jagtap, A. D., Kondekar, N. B., Hung, P.-Y., Hsieh, C.-E., Yang, C., Chen, G. S., & Chern, J. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103135 · Cited by 17
Synonymous variants associated with Alzheimer disease in multiplex families
Tang, M., Alaniz, M. E., Felsky, D., Vardarajan, B. N., Reyes‐Dumeyer, D., Lantigua, R., Medrano, M. Z., Bennett, D. A., Jager, P. L. D., Mayeux, R. P., et al. (2020) · Neurology Genetics · doi:10.1212/nxg.0000000000000450 · Cited by 21
Resende, R., Ferreira‐Marques, M., Moreira, P., Coimbra, J. R. M., Baptista, S. J., Isidoro, C., Salvador, J. A. R., Dinis, T. C. P., Pereira, C., & Santos, A. E. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200381 · Cited by 17
Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia
Lee, J. Y., Marian, O. C., & Don, A. S. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-021-08644-4 · Cited by 20
Li, X., Zhang, J., Yang, Y., Wu, Q., & Ning, H. (2021) · Cell Biology International · doi:10.1002/cbin.11576 · Cited by 20
“AD, as the primary cause of dementia in the elderly, is one of the most alarming neurodegenerative disorders around the world (Jonsson et al., 2012).”
BackgroundAn, F.-M., Liu, Z., Xuan, X., Liu, Q., & Wei, C. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114002 · Cited by 19
Searching the Dark Genome for Alzheimer’s Disease Risk Variants
Raybould, R., & Sims, R. (2021) · Brain Sciences · doi:10.3390/brainsci11030332 · Cited by 19
“[20] WGS, Illumina bead chip, and imputation Icelandic 1795 WGS 71743 chip Coding mutation A673T in APP protects against AD.”
BackgroundNext Generation Sequencing in Alzheimer’s Disease
Bertram, L. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2627-5_17 · Cited by 19
Cerebrospinal fluid biomarkers of Alzheimer’s disease
Sui, X., Liu, J., & Yang, X. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1412-1 · Cited by 19
“Aβ is a proteolytic cleavage product of amyloid precursor protein (APP) [22] [23] .”
BackgroundAssessing association between protein truncating variants and quantitative traits
Rivas, M. A., Pirinen, M., Neville, M., Gaulton, K. J., Moutsianas, L., Lindgren, C. M., Karpe, F., McCarthy, M. I., & Donnelly, P. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt409 · Cited by 20
“To improve power, a common approach is to combine statistical evidence from several genetic variants in a region.”
MethodMunter, L. M., Sieg, H., Bethge, T., Liebsch, F., Bierkandt, F. S., Schleeger, M., Bittner, H. J., Heberle, J., Jakubowski, N., Hildebrand, P. W., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja410812r · Cited by 22
Ye, N., Monk, S. A., Daga, P., Bender, D. M., Rosen, L. B., Mullen, J., Minkwitz, M. C., & Kugler, A. R. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.422 · Cited by 19
Binding Modes of Phthalocyanines to Amyloid β Peptide and Their Effects on Amyloid Fibril Formation
Valiente‐Gabioud, A. A., Riedel, D., Outeiro, T. F., Menacho-Márquez, M., Griesinger, C., & Fernández, C. O. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.01.003 · Cited by 18
Izuo, N., Murakami, K., Fujihara, Y., Maeda, M., Saito, T., Saido, T. C., Irie, K., & Shimizu, T. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.05.131 · Cited by 19
Deerlin, V. M. V. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1032-2 · Cited by 18
“Recently, an APP variant which may actually reduce the risk for AD was identified by genome sequencing in an Icelandic population [20].”
Naj, A. C., Leonenko, G., Jian, X., Grenier‐Boley, B., Dalmasso, M. C., Bellenguez, C., Jin, S., Zhao, Y., van der Lee, S. J., Sims, R., et al. (2021) · medRxiv · doi:10.1101/2021.03.14.21253553 · Cited by 23
Failure analysis of clinical trials to test the amyloid hypothesis
Hyman, B. T., & Sorger, P. K. (2014) · Annals of Neurology · doi:10.1002/ana.24227 · Cited by 16
Current status of vaccination therapies in Alzheimer's disease
Karran, E. H. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12009 · Cited by 17
“Indeed, mutations to the APP gene that have the effect of modestly reducing the production of Abeta peptide from the APP holoprotein have recently been shown significantly to protect carriers from AD – a natural, genetic proof of concept (Jonsson et al. 2012).”
BackgroundKobro‐Flatmoen, A., Battistin, C., Nair, R. R., Bjorkli, C., Skender, B., Kentros, C. G., Gouras, G. K., & Witter, M. P. (2023) · Brain Communications · doi:10.1093/braincomms/fcad115 · Cited by 18
“Third, a genetic variant in humans that results in less Aβ protects against Alzheimer’s disease.(7)”
BackgroundLessard, S., Chao, M. J., Reis, K., FinnGen, Rajpal, D. K., Shankara, S., Sloane, J., Palta, P., Klinger, K. W., de Rinaldis, E., et al. (2024) · BMC Genomics · doi:10.1186/s12864-024-10971-2 · Cited by 22
“We also identified protective variants such as APP p.Ala673Thr (rs63750847, P = 7 × 10 − 11 ) reducing odds of developing AD [90], and ALOX15 p.Thr560Met protecting against nasal polyps (rs34210653, P = 2 × 10 − 15 ) [91].”
Targeting ubiquilin-1 in Alzheimer's disease
Takalo, M., Haapasalo, A., Natunen, T., Viswanathan, J., Kurkinen, K. M. A., Tanzi, R. E., Soininen, H. S., & Hiltunen, M. O. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.791284 · Cited by 18
“Conversely, a recent report shows that a naturally occurring, low-frequency variant of APP (A673T) protects from the AD- and age-related cognitive decline by reducing BACE1mediated cleavage of APP and thus lowering the production of Ab [9].”
BackgroundQiu, F., Yang, L., Lu, X., Chen, J., Wu, D., Wei, Y., Nong, Q., Zhang, L., Fang, W., Chen, X., et al. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005955 · Cited by 17
Analyzing the Behavior of Neuronal Pathways in Alzheimer's Disease Using Petri Net Modeling Approach
Ashraf, J., Ahmad, J., Ali, A., & Ul‐Haq, Z. (2018) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2018.00026 · Cited by 17
“Abnormal processing of APP is stated to be the first and fundamental step in plaques formation in AD pathogenesis (Jonsson et al., 2012).”
BackgroundGenome-wide association study identifies quantitative trait loci affecting cattle temperament
Shen, J., 西北农林科技大学动物科技学院, 陕. 杨. 7., Chen, Q.-M., Zhang, F., Hanif, Q., Huang, B., Chen, N., Qu, K., Zhan, J., Chen, H., et al. (2021) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2021.176 · Cited by 22
“Among these genes, amyloid-β precursor protein (APP) is well-known, with a mutation found to be protective against Alzheimer’s disease and age-related cognitive decline (Jonsson et al., 2012).”
Ribeiro, H. F., Santos, J. S. F. D., & Souza, J. N. D. (2021) · Revista de Neuro-Psiquiatría · doi:10.20453/rnp.v84i2.3998 · Cited by 34
“A propriedade antiamiloidogênica é identificada no estado de heterozigose (30).”
BackgroundCannabinoids – a new therapeutic strategy in neurology
Sîrbu, C. A., Manole, A. M., Vasile, M., Toma, G. S., Dobrican, L. R., Varvara, D. G., & Vasiliu, O. (2022) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2022.125.3.1 · Cited by 14
Alzheimer's disease clinical trials: past failures and future opportunities
Yaari, R., & Hake, A. M. (2015) · Clinical Investigation · doi:10.4155/cli.14.127 · Cited by 17
Unlocking Truths of γ-Secretase In Alzheimer'S Disease: What Is the Translational Potential?
Wolfe, M. S. (2014) · Future Neurology · doi:10.2217/fnl.14.35 · Cited by 18
A novel approach for multi-SNP GWAS and its application in Alzheimer’s disease
Initiative, T. A. D. N., Bodily, P., Fujimoto, M., Page, J. T., Clement, M., Ebbert, M., & Ridge, P. G. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1093-7 · Cited by 18
“In contrast, all of the other known variations that affect risk for AD are either very rare (PLD3 [11], APP [13], TREM2 [12], etc.”
BackgroundlncRNAs, DNA Methylation, and the Pathobiology of Exfoliation Glaucoma
Johnson, W. M., Finnegan, L. K., Hauser, M. A., & Stamer, W. D. (2017) · Journal of Glaucoma · doi:10.1097/ijg.0000000000000711 · Cited by 18
Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome
Caprini, E., Bresin, A., Cristofoletti, C., Citterich, M. H., Tocco, V., Scala, E., Monopoli, A., Benucci, R., Narducci, M. G., & Russo, G. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1212-7 · Cited by 18
Lawingco, T., Chaudhury, S. R., Brookes, K. J., Guetta‐Baranes, T., Guerreiro, R. J., Brás, J., Hardy, J., Francis, P. T., Thomas, A. J., Belbin, O., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.11.009 · Cited by 20
Svedružić, Ž. M., Popović, K., & Jengić, V. Š. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.06.002 · Cited by 17
“Notably different is A673T mutation in APP protein, a protective mutation at the β-secretase cleavage site that leads to decrease in production of β-CTF-APP substrate and decrease in Aβ production (Jonsson et al., 2012).”
InfluentialHuman Genetics and Clinical Aspects of Neurodevelopmental Disorders
Lyon, G. J., & O'Rawe, J. (2015) · Wiley eBooks · doi:10.1002/9781118524947.ch13 · Cited by 16
Honda, K., Saito, Y., Saito, H., Toyoda, M., Abe, R., Saito, T., Saido, T. C., Michikawa, M., Taru, H., Sobu, Y., et al. (2022) · SSRN Electronic Journal · doi:10.1016/j.neurobiolaging.2022.12.003 · Cited by 17
Ding, L., Meng, Y., Zhang, H., Yin, W., Yan, Y., & Cao, Y. (2017) · Neuroscience Research · doi:10.1016/j.neures.2017.01.003 · Cited by 16
Dalvi, T., Dewangan, B., Agarwal, G., Suchita, D. S., Jain, A. K., Srivastava, A., & Sahu, B. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127999 · Cited by 16
Nithianandam, V., Bukhari, H., Leventhal, M. J., Battaglia, R. A., Dong, X., Fraenkel, E., & Feany, M. Β. (2023) · Nature Communications · doi:10.1038/s41467-023-42822-1 · Cited by 18
“ubiquitin (1:1000, P4G7, BioLegend; 1:200 Cell Signaling; 1:200, Z0458, Dako), GABARAP 529 (1:1,000, endogenous Drosophila Atg8a, E1J4E, Cell Signaling; 1:200, Abcam), LC3B (1:200, 530 Novus Biologicals), ref(2)P (1:600, Sarkar et al.”
Komal, K., Ghosh, R., Sil, D., Sharma, R., Kumar, S., Pandey, P., & Kumar, M. (2025) · Inflammopharmacology · doi:10.1007/s10787-024-01636-3 · Cited by 16
Berger–Sieczkowski, E., Milenković, I., Venkataramani, V., Giera, R., Ströbel, T., Höftberger, R., Liberski, P. P., Auff, E., Wirths, O., Bayer, T. A., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141524 · Cited by 19
“Assuming that there are not only pathogenic but as well protective mutations [64] described in the AβPP gene, an accurate evaluation of each mutation is of outmost importance and may have diagnostic and therapeutic implications.”
Translating Neurogenomics Into New Medicines
Wendland, J. R., & Ehlers, M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.04.027 · Cited by 17
Selective manipulation of aging: a novel strategy for the treatment of neurodegenerative disorders
Cohen, E., Moll, L., & Elami, T. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.13917 · Cited by 18
Endogenous APP accumulates in synapses after BACE1 inhibition
Nigam, S. M., Xu, S., Ackermann, F., Gregory, J. A., Lundkvist, J., Lendahl, U., & Brodin, L. (2016) · Neuroscience Research · doi:10.1016/j.neures.2016.02.002 · Cited by 16
“The exact cause of the synaptic impairment is unclear, but many lines of evidence indicate that amyloid peptides (A ) derived from the proteolytic processing of the amyloid precursor protein (APP) plays a central role (Haass et al., 2012; Jonsson et al., 2012; Selkoe et al., 2012).”
BackgroundPiccoli, E., Rossi, G., Rossi, T., Pelliccioni, G., D’Amato, I., Tagliavini, F., & Fede, G. D. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.01.134 · Cited by 16
“Moreover, rare variants associated with LOAD have also been identified in APP, TREM2, and PLD3 genes (Cruchaga et al., 2014; Guerreiro et al., 2013; Jonsson et al., 2012).”
BackgroundBiundo, F., Ishiwari, K., Prete, D. D., & D'adamio, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7389 · Cited by 17
“Indeed, APP mutations that alter APP processing either protect from sporadic AD or cause familial AD; additionally, mutations in genes that regulate APP processing -such as PSENs and BRI2/ITM2B- cause FAD, FBD and FDD [1-12].”
Background
Metadata
- Authors
- Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A., Jönsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J., & Stefansson, K.
- Affiliations
- Genentech (US)
- deCODE Genetics (Iceland) (IS)
- University of Oslo (NO)
- Karolinska Institutet (SE)
- University of Helsinki (FI)
- ORCID
- Venue
- Nature
- Published
- 2012-07-11
- Volume
- 488
- Issue
- 7409
- Pages
- 96-99
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2154755614
- Cited by
- 1,738
- References
- 26
- Citations by year
- 2026: 56 · 2025: 72 · 2024: 93 · 2023: 94 · 2022: 70 · 2021: 120 · 2020: 134 · 2019: 107 · 2018: 134 · 2017: 145 · 2016: 155 · 2015: 166 · 2014: 173 · 2013: 154 · 2012: 60
- FWCI
- 119.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL-102924, HL-102925, HL 103010, HL-102926)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, amyloid precursor protein, APP gene, protective genetic variants, cognitive decline in older adults, amyloid plaques, β-cleavage, amyloidogenic peptides, genetic risk, Icelandic population
- MeSH terms
- Aging, Alleles, Alzheimer Disease, Cognition, Cognition Disorders, Humans, Mutation, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Amyloid Precursor Protein Secretases, HEK293 Cells, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.